EXICURE, INC. Undergoes Major Leadership Overhaul Amidst Strategic Pivot and Financial Challenges

EXICURE, INC. faces a pivotal moment, announcing a sweeping leadership change designed to steer the company through a challenging period. This executive overhaul follows the devastating failure of its flagship drug, forcing EXICURE to forge a new strategic direction.

The Leadership Change

On February 9, 2026, EXICURE's CEO and President, Andy Yoo, and CFO and Secretary, Seung Ik Baik, resigned. Just two days later, on February 11, 2026, EXICURE appointed Jung Soo Kim as the new CEO and President, and Gyuyeob Lee as the Interim Chief Financial Officer and Secretary. The company publicly disclosed these changes in an SEC filing on February 17, 2026.

Significantly, Mr. Kim and Mr. Lee join EXICURE through Innocircle Advisors Inc. This arrangement suggests EXICURE is bringing in specialized turnaround expertise, likely on a consulting or interim basis, rather than traditional full-time employment. This implies a focused, time-limited engagement to stabilize the company or execute a specific strategic plan.

Why This Change is Happening Now: The NeuroCure Setback and Financial Realities

This executive overhaul directly responds to the devastating failure of EXICURE's flagship drug candidate, "NeuroCure." In late 2023, NeuroCure, intended as the company's primary revenue driver (its specific therapeutic indication was not detailed), failed its Phase 3 clinical trials. This failure means the drug did not meet its primary efficacy endpoints or faced significant safety concerns, effectively halting its development.

Losing its flagship product leaves EXICURE in a highly precarious financial and strategic position. While the filing did not disclose specific financial figures, the context strongly suggests EXICURE faces significant financial challenges, including a limited cash runway and the urgent need for a new strategic direction and potential capital infusion. The board of directors likely initiated this leadership change to bring in fresh perspectives and expertise specifically tailored to navigate such a difficult turnaround.

What the New Leadership Brings to the Table

The backgrounds of the new executives are particularly relevant to EXICURE's current predicament:

• Jung Soo Kim (CEO & President): Mr. Kim brings over 20 years of experience in corporate strategy, mergers & acquisitions (M&A), and business reorganization, having previously served as CEO and director at tech companies like AGEDB Technology Ltd. and Sandcraft Inc. His background suggests EXICURE may explore significant strategic pivots, potential asset acquisitions or divestitures, or even a complete restructuring of its business model.
• Gyuyeob Lee (Interim CFO & Secretary): Mr. Lee offers expertise in financial planning, corporate governance, and complex project management, with experience at AGEDB Technology and GS Engineering & Construction. His appointment as Interim CFO, especially through Innocircle Advisors, underscores the immediate need for robust financial management, capital markets expertise, and potentially securing new funding or managing existing resources more effectively.

Their combined experience points towards a leadership team focused on financial discipline, strategic re-evaluation, and potentially aggressive measures to secure EXICURE's future.

Impact and What's Next for Investors

This leadership change marks a pivotal moment for EXICURE, signaling a "reset" for a company that lost its primary asset and now faces an uncertain future.

• For EXICURE: EXICURE must now articulate a clear new strategy. This could involve identifying other potential drug candidates within its existing intellectual property (if any), exploring new therapeutic areas, seeking partnerships, or even considering a reverse merger or sale. Its financial health will dictate the urgency and nature of these decisions.
• For Investors: This is a high-stakes situation. EXICURE's stock likely saw significant volatility and a decline after the NeuroCure failure. While new leadership offers a glimmer of hope for a turnaround, the path ahead remains risky. Investors should anticipate continued volatility as the market awaits concrete plans from the new leadership.

Key Investor Takeaways:

1. A New Chapter, Not a Guarantee: This leadership change signals EXICURE's attempt to recover from the NeuroCure setback, but success is far from assured.
2. Focus on Strategy and Financials: The immediate focus shifts to the new leadership's announcements regarding the company's strategic direction, its remaining assets or pipeline, and critically, its financial plans for continued operations.
3. High Risk, Potential for Rebound: EXICURE remains a high-risk investment given its current challenges. However, a successful strategic pivot and effective capital management by the new leadership could potentially lead to a rebound.
4. Monitor Innocircle Advisors Arrangement: The nature of the new executives' engagement through Innocircle Advisors Inc. warrants close attention, as it may indicate the duration or specific mandate of their roles.
5. Biotech Volatility: This situation underscores the inherent volatility and risk in biotech investing, where a single clinical trial outcome can dramatically alter a company's trajectory and leadership.

Investors should closely monitor EXICURE's upcoming announcements for specific details on its strategic review, financial runway, and any plans for new product development or corporate restructuring.